lifestyle.pspl.com

Author: InnoCare Pharma

InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China

May 7, 2026
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

May 7, 2026
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE

May 6, 2026
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

May 5, 2026
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety

May 5, 2026
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

May 2, 2026
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China

April 30, 2026
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

March 1, 2026
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

February 13, 2026
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

February 12, 2026